By Rebecca Beyer
Daily Journal Staff Writer A San Francisco federal judge again has rejected plaintiffs' arguments that New York-based Pfizer's $68 billion acquisition of Wyeth will decrease competition in the pharmaceutical drug market. U.S. Senior District Judge Maxine M. Chesney on Wednesday dismissed the first amended complaint against the companies, finding it failed to allege how the merger would negatively affect specific products. Chesney dismissed the or...
Daily Journal Staff Writer A San Francisco federal judge again has rejected plaintiffs' arguments that New York-based Pfizer's $68 billion acquisition of Wyeth will decrease competition in the pharmaceutical drug market. U.S. Senior District Judge Maxine M. Chesney on Wednesday dismissed the first amended complaint against the companies, finding it failed to allege how the merger would negatively affect specific products. Chesney dismissed the or...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In